The Spanish Menopause Society published an expert position statement on 25 August covering the use of GLP-1 and dual incretin medications in peri- and postmenopausal women with overweight or obesity. It sets out 20 positions across body composition, cardiometabolic risk, musculoskeletal health, monitoring and interaction with hormone therapy. The most useful thing in it, for … Read more
A systematic review and meta-analysis published on 29 August pooled nine randomised trials covering 6,239 adults with overweight or obesity but without diabetes, and found that injected semaglutide reduced a standard marker of inflammation by roughly 40% alongside the weight loss it is prescribed for. Serious adverse events were no more common than on placebo. … Read more
A case report published on 26 August describes a man in his mid-30s with long-standing type 1 diabetes who was admitted to hospital with severe vomiting, diarrhoea, high blood sugar, ketones and acute kidney injury, shortly after self-administering a product he had bought online marketed as retatrutide. His partner took the same preparation and also … Read more
Eli Lilly reported on 23 July 2026 that retatrutide, an investigational triple hormone receptor agonist, met its primary endpoint in two further Phase 3 trials. Participants with obesity and type 2 diabetes lost up to an average of 20.8% of body weight over 80 weeks; those with severe obesity and established cardiovascular disease lost up … Read more
The FDA has approved a new indication for Mounjaro (tirzepatide): lowering the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes who are at high risk for them. Eli Lilly announced the approval on 28 August 2026. It is the first cardiovascular … Read more
A large propensity-matched cohort study published in Diabetes, Obesity and Metabolism on 27 August 2026 found that people who started a GLP-1 receptor agonist were modestly more likely to be diagnosed with diabetic retinopathy, and more likely to undergo a retinopathy procedure, than matched people who started a DPP-4 inhibitor instead. The same study found … Read more
Trial results describe what happens under close supervision with motivated volunteers. A study published in August in The Lancet Diabetes & Endocrinology asked a harder question: among 45,093 real patients with obesity and type 2 diabetes, how many actually hit a meaningful combined target a year after starting treatment? The answer for semaglutide was 3.0%. … Read more
Eli Lilly announced on 26 August 2026 that a real-world analysis of adults over 55 found lower healthcare costs among people who stayed on Zepbound (tirzepatide) than among matched untreated adults, and framed the result against the $195 monthly net price under Medicare’s GLP-1 Bridge programme. The underlying paper is peer-reviewed and published in Diabetes, … Read more